Puretech Health Share Discussion Threads

[edwardt] 15/11/2018 16:14

lendme - what else have you tucked away that could 10 bag like prtc?

[lendmeafiver] 15/11/2018 14:18

I have always looked at puretech as it’s base market capitalisation being covered by its 21% holding of Gelesis and it’s cash, the other potentials such as Akili, Restorbio, Vedandta, alivio and follica are all in for free with the individual potential for Billion dollar upside to the market cap.

Certainly seems to be a very steady and controlled rise in buying interest here also, especially given the volitility in the uk markets at the moment.

Will check the FD out later today, thanks.

[edwardt] 15/11/2018 13:12

listened to the fd - available on puretech website - i think i am going to revise my answer and go for akili - it seems a great solution for adhd and the notion it could be applied to depression too could be the game changer (no pun intended).

[lendmeafiver] 14/11/2018 10:44

Maybe Follica will bring the retail punters!

[edwardt] 14/11/2018 08:46

where's teh retail punters coming in on the back of that - it is usually worth 10 points on the stock!

[lendmeafiver] 13/11/2018 13:18

We have made it into the Daily Telegraph:

[edwardt] 08/11/2018 10:13

restorbio would be my guess. the americans will bid it up big time if all goes well.

[lendmeafiver] 07/11/2018 21:30

I think Gelesis has huge potential and for me backs up the market cap here alone.

What’s you view on the Puretech Division that will drive this to 10 bag?

[lendmeafiver] 07/11/2018 15:53

It is, shame so few here.

Gelesis news flow next week also.

[edwardt] 07/11/2018 15:18

can not say i fully understand but it does look excited?
eclinical data showed that VE800 induced a systemic, anti-tumour immune response both as a monotherapy and in combination with checkpoint inhibitors. Additionally, the results describe a mechanism of action for VE800 as the robust interferon-gamma producing CD8+ (cytotoxic) T cell response was elicited via activation of dendritic cells

[edwardt] 16/10/2018 16:26

restorbio . when you read that rns and i am no expert but all i think is wow when i think how exciting / $$$$ that business may well be....

[lendmeafiver] 09/10/2018 18:26

75000 buy this afternoon

[zeusfurla] 04/10/2018 07:39

Positive RNS today.

[countless] 27/9/2018 10:27

Without news I expect this will drift down a bit.

[lendmeafiver] 15/9/2018 23:12

Plus resTORbio heading up on the Nasdaq also.

[rambutan2] 15/9/2018 20:20

From citywire:

PureTech Health (PRTC) shares are ‘too cheap’ following strong progress since the start of the year, including a potential $1 billion licensing deal with Roche, says Liberum.

Analyst Roger Franklin retained his ‘buy’ recommendation and target price of 248p on the shares, which were trading at 158.8p yesterday.

He said PureTech was ‘pioneering a new way to pursue biotech and pharma research and development’ and ‘given the nature of the company, the financial results are as usual a sideshow to the main focus which is the progress of its affiliates and internal pipeline’.

Franklin noted the company’s more than $1 billion potential licensing deal with Roche which ‘demonstrates strong progress since the start of the year’.

‘The shares remain too cheap in our view, with our asset based target price of 248p offering more than 50% upside,’ he said.

[lendmeafiver] 14/9/2018 15:16

The buying continues today, looking good

[lendmeafiver] 13/9/2018 20:25

Bit of buying since the Half Year Results, not surprising.

[lendmeafiver] 11/9/2018 22:37

Jefferies Buy 255.00 Reiteration

[countless] 11/9/2018 09:40

Cash in in bank wrong exression but their possition is improving in leaps and bounds - total assets up 28% total liabilites down 21% and after a very busy period costs/loss down 2.7% Seems stran to me me that healthcare based businesses are flying with no knock on effect here given strong pipeline that reaches out to some mass markets.

[lendmeafiver] 11/9/2018 09:12

“Moon shots” is an excellent description!

[edwardt] 11/9/2018 09:07

agreed - patience is required but we have several moon shots all jockying for position at the launch pad.

[lendmeafiver] 11/9/2018 08:56

Even Follica gets a “significant progress towards the initiation of a pivotal study in androgenetic alopecia” normally they downplay that opportunity, plus have included it in the next 12 month milestone section. Newsflow over the next 12 months over all divisions now very significant.